Owens, Trevor by unknown
Syddansk Universitet
Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination








Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Berg, C. T., Khorooshi, R. M. H., Asgari, N., & Owens, T. (2017). Influence of type I IFN signaling on anti-MOG
antibody-mediated demyelination. Journal of Neuroinflammation, 14, 127-134. DOI: 10.1186/s12974-017-0899-1
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Jul. 2017
SHORT REPORT Open Access
Influence of type I IFN signaling on anti-
MOG antibody-mediated demyelination
Carsten Tue Berg1, Reza Khorooshi1, Nasrin Asgari1,2 and Trevor Owens1*
Abstract
Background: Antibodies with specificity for myelin oligodendrocyte glycoprotein (MOG) are implicated in multiple
sclerosis and related diseases. The pathogenic importance of anti-MOG antibody in primary demyelinating
pathology remains poorly characterized.
Objective: The objective of this study is to investigate whether administration of anti-MOG antibody would be
sufficient for demyelination and to determine if type I interferon (IFN) signaling plays a similar role in anti-MOG
antibody-mediated pathology, as has been shown for neuromyelitis optica-like pathology.
Methods: Purified IgG2a monoclonal anti-MOG antibody and mouse complement were stereotactically injected
into the corpus callosum of wild-type and type I IFN receptor deficient mice (IFNAR1-KO) with and without pre-
established experimental autoimmune encephalomyelitis (EAE).
Results: Anti-MOG induced complement-dependent demyelination in the corpus callosum of wild-type mice and
did not occur in mice that received control IgG2a. Deposition of activated complement coincided with
demyelination, and this was significantly reduced in IFNAR1-KO mice. Co-injection of anti-MOG and complement at
onset of symptoms of EAE induced similar levels of callosal demyelination in wild-type and IFNAR1-KO mice.
Conclusions: Anti-MOG antibody and complement was sufficient to induce callosal demyelination, and pathology
was dependent on type I IFN. Induction of EAE in IFNAR1-KO mice overcame the dependence on type I IFN for
anti-MOG and complement-mediated demyelination.
Keywords: Beta-interferon, Demyelination, Histopathology, Immunology, Animal model, Experimental autoimmune
encephalomyelitis, Multiple sclerosis
Introduction
Multiple Sclerosis (MS) is an inflammatory demyelinat-
ing disease of the central nervous system (CNS) with a
complex pathogenesis [1]. MS pathology has been char-
acterized by chronic inflammation, which leads to focal
plaques of demyelination in the white matter [2]. More
than 50% of MS lesions show complement (C) and im-
munoglobulin G (IgG) deposition on demyelinating
axons, classified as type II pathology [3, 4], but there is
no consensus as to either the specificity or pathologic
role of IgG antibodies in blood or cerebrospinal fluid
(CSF) of MS patients [1]. Plasma exchange, which
removes IgGs, as well as immune complexes and
cytokines, was effective for a group of patients con-
firmed to have had type II MS pathology [5]. This sug-
gests that antibody and C are effectors of pathology in
MS. Localization of C deposition has been shown in
areas of active demyelination in patients with IgG myelin
oligodendrocyte glycoprotein (MOG)-antibody-associated
encephalomyelitis and pattern II MS [6–8]. One candidate
autoantigen in MS is MOG, which is expressed by oligo-
dendrocytes and on the outermost surface of the myelin
sheath [9, 10]. Autoantibodies against MOG are impli-
cated in pediatric MS [11] and acute disseminated en-
cephalomyelitis (ADEM) [12] as well as in a subset of
water channel aquaporin-4 (AQP4)-IgG seronegative neu-
romyelitis optica spectrum disorder (NMOSD) [13–15].
The most extensively used animal model of MS, experi-
mental autoimmune encephalomyelitis (EAE), is an
adjuvant-driven experimental autoimmune disease, which
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in most formulations is dependent on CD4+ T cells. In a
commonly used EAE variant, immunization of C57BL/6
mice with an encephalitogenic peptide (MOG p35–55) in-
duces a chronic inflammatory demyelinating disease that
has been shown to be independent of IgG or B cells [16],
whereas immunization with recombinant human MOG or
a fusion protein of myelin basic protein and proteolipid
protein induces EAE that is dependent on B cells and anti-
body [17–20]. It has previously been shown that injection
of monoclonal antibody against MOG into Lewis rats with
EAE induced demyelination [21, 22]. Serum from guinea
pigs with chronic-relapsing EAE could also induce demye-
lination, when transferred into subarachnoid space of nor-
mal rats and the degree of demyelination correlated with
high titers of anti-MOG antibody in serum [22]. However,
direct demonstration of demyelination induced by MOG-
specific antibody has not been reported. We have previ-
ously demonstrated complement-dependent astrocyto-
pathology and demyelination in mice that received
neuromyelitis optica (NMO) patient-derived IgG [23]. We
also showed a requirement for type I IFN signaling for
NMO-like pathology, showing that it was reduced in mice
lacking the receptor for type I IFN [24]. This observation
aligned with clinical findings that recombinant IFN-β is
not an effective therapy for NMO whereas it shows effect
for MS [25–27]. Interestingly, MOG-IgG-positive patients
also showed increased disease activity under treatment
with IFN-β [14, 28]. The objective of this study was to ex-
tend those findings, to investigate whether IFNAR de-
pendency would be seen for other antibody specificities.
We chose to test a monoclonal MOG-specific antibody.
This required establishing that anti-MOG antibody is suf-
ficient to induce primary demyelinating pathology and
then to ask whether and how type I IFN signaling affects
that pathology in mice with and without EAE.
Materials and methods
Mice
Adult female C57BL/6 mice aged 8–12 weeks were
purchased from Taconic Europe (Ry, Denmark), and
adult female type I IFN receptor deficient mice
(IFNAR1-KO) aged 8–12 on C57BL/6 background
were bred from mice originally provided by Dr.
Marco Prinz. NOD-Scid/J immunodeficient mice aged
8–12 with impaired T and B cell lymphocyte develop-
ment were obtained from Prof. Moustapha Kassem.
All experiments were conducted in accordance with the
Danish Animal Experiments Inspectorate (approval
number 2014-15-0201-00369).
EAE induction
C57BL/6 and IFNAR1-KO mice were immunized with
MOG p35–55 (sequence MEVGWYRSPFSRVVHLYRNGK),
obtained from TAG Copenhagen A/S in Denmark.
Emulsions of MOG p35–55 (300 μg) and complete
Freund’s adjuvant with heat-inactivated Mycobacter-
ium tuberculosis (200 μg; BD-Biosciences, Sparks,
USA) were injected subcutaneously into each hind
flank. Animals received an intraperitoneal injection of
pertussis toxin (0.3 μg; Sigma-Aldrich, Brøndby,
Denmark) at the time of immunization and 2 days
post-immunization. Mice were monitored for the loss
of body weight and EAE symptoms as described pre-
viously [29].
Intracorpus callosum injection
Mice were anesthetized using hypnorm (fluanisone/
fentanyl) in combination with midazolam. Intra-
corpus callosum (CC) injections were performed using
the following stereotactic coordinates relative to
bregma: 1 mm anterior, 1 mm lateral, and −1.6 ven-
tral. Anti-MOG IgG2a (15 μg/mouse) (protein G af-
finity purified supernatant from hybridoma clone Z2
developed by Prof. Chris Linington and IgG2a isotype
control from murine myeloma (Sigma-Aldrich,
Brøndby, Denmark) were used in the experiments.
Mice received intra-CC injection (5 μl) of anti-MOG
Ab or control IgG2a together with 2 μl mouse C
(Sigma-Aldrich; Cedarlane, Burlington, Canada). The
mice were euthanized 2 days post-injection with an
overdose of pentobarbital (0.2 mg per gram body
weight, Glostrup Apotek, Glostrup, Denmark) and
perfused transcardially with ice-cold phosphate buff-
ered saline (PBS). For q-RT-PCR analysis, CNS tissue
were dissected and immediately placed in TRIzol re-
agent and stored at −80 °C until further q-RT-PCR
processing. For histology, mice were additionally per-
fused with 4% PFA in PBS. After removal, CNS tissue
was post-fixed in 4% paraformaldehyde, immersed in
30% sucrose in PBS at 4 °C overnight, frozen with li-
quid nitrogen and stored at −80 °C until sections
were cut on a cryostat.
RNA extraction, reverse transcription, and quantitative
real-time PCR
RNA was extracted from brain tissue using TRIzol re-
agent (Invitrogen-Molecular Probes, Eugene OR USA)
in accordance with the manufacture’s protocol. One
microgram of total RNA was reverse transcribed using
M-MLV reverse transcriptase (Invitrogen) according to
the manufacturer’s protocol. The following sequence-
specific primers and probes were used for IFN-β and
CXCL10: IFN-β: For: GCGTTCCTGCTGTGCTTCTC;
Rev: TTGAAGTCCGCCCTGTAGGT; Probe: CGG
AAATGTCAGGAGCT; CXCL10: For: GCCGT CA
TTTTCTGCCTCAT; Rev: GGCCCGTCATCGATAT
GG; Probe: GGACTCAAGGGATCC. All samples were
run as triplicates and plates detecting the same gene
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were normalized using a generalized sample of cDNA.
The relative quantitation of gene expression was deter-
mined using the delta cycle threshold (ΔCt) method.
Histochemistry and immunohistochemistry
For routine histology, 12-μm thick sections were cut
from frozen brain and spinal cord tissue and mounted
on Superfrost® Plus (Thermo Scientific, Braunschweig,
Germany) slides and stained using luxol fast blue (LFB)
and hematoxylin and eosin (H&E) staining. Immunohis-
tochemical staining used to identify and examine C de-
position, astrocyte and microglia activation were
performed by sequential antibody incubations and detec-
tion. The primary antibody used to identify C deposition,
activation of astrocytes, and microglia were C9neo
(rabbit polyclonal anti-C5b-9, 1:100, Abcam, Cambridge,
UK), GFAP (rabbit anti-mouse glial fibrillary acidic
protein, 1:500, Dako, Glostrup, Denmark), and Iba-1
(rabbit anti-ionized calcium binding adapter molecule
1 (1:500, Waco, Osaka, Japan), respectively. The sec-
ondary antibodies were goat anti-rabbit conjugated
with biotin (Abcam, 1:1, Cambridge, UK) followed by
streptavidin-horseradish peroxidase (streptavidin-HRP,
1:200, Amersham Biosciences, Little Buckinghamshire,
UK) and DAB detection (3,3′-diaminobenzidine,
0.5 mg/ml, Sigma Aldrich). For double staining for infil-
tration of CD45-positive cells and laminin, frozen brain
sections were incubated with primary antibodies––rat
anti-mouse CD45 conjugated with PE (BD Biosciences,
San Diego, CA, USA (1:300)) and rabbit anti-mouse
laminin (Cederlane 1:100)––and the corresponding
fluorophore-conjugated secondary antibody––donkey
anti-rabbit IgG conjugated with Alexa fluor 488
(Invitrogen 1:200). Cellular nuclei were visualized by the
use of 4,6-diamino-2-phenylindol (DAPI, Invitrogen) di-
luted in PBS.
Quantitation of histological and immunohistochemical
findings
For all analyses, brain and spinal cord sections were
coded, analyzed, and quantified blindly. The area of de-
myelination in CC was quantitated using ImageJ soft-
ware. The number of infiltrating cells in the CC was
determined manually by counting the number of CD45
positive cells. The evaluation of the activation of astro-
cytes and microglia in and around demyelinated areas
was performed blinded and semi-quantitatively using a
scale from 0 to 3 as described [23].
Data presentation and statistical analysis
All experiments were repeated at least three times, and
data are presented as mean ± standard error of mean
(SEM). Statistical significance was assessed by the two-
tailed Mann–Whitney U test using GraphPad prism v. 6.0e
software (GraphPad Software, USA). P values <0.05 were
considered as evidence of statistical significance.
Results
Callosal demyelination by anti-MOG and complement
To investigate whether a monoclonal MOG-specific
antibody would be sufficient to induce MS-related path-
ology in the presence of C, we injected 5, 15, and 30 μg
anti-MOG into CC and examined pathology 2 days later.
Focal pathology corresponding to antibody and C-
mediated damage was observed at the site of injection,
in the CC. Significant demyelination was detectable at
anti-MOG ≥15 μg, and this dose was used in all subse-
quent experiments (Fig. 1a). Demyelination was
dependent on co-injection of C, and did not occur in
mice that received anti-MOG alone, or control IgG2a
with C (Fig. 1b, c). Deposition of activated C could be
demonstrated at the same site as demyelination (Fig. 1b).
Some inflammation was seen, which was accounted
for by the trauma of needle insertion.
A few CD45-positive cells were located mainly within
the needle track. We also observed activation of astro-
cytes (GFAP staining) and microglia (Iba1 staining) in
and around demyelinated areas (Fig. 2a).
Demyelination was equivalent in NOD-Scid/J immuno-
deficient mice to which anti-MOG + C was injected into
the CC (Fig. 1c). This shows that anti-MOG + C-mediated
demyelination is independent of B and T cells.
Induction of type I IFN and influence of type I IFN
signaling on anti-MOG antibody-mediated demyelination
We used RT-qPCR to evaluate gene expression for IFN-
beta (IFN-β), a type I IFN, and the IFN-induced chemo-
kine CXCL10, in brain RNA isolates. We observed high
expression of IFN-β mRNA compared to controls
(Fig. 2b). Additionally, we observed a significant increase
in gene expression for CXCL10. This points to a poten-
tial role for type I IFN signaling in antibody-mediated
demyelination. We further investigated whether injec-
tion of anti-MOG + C led to pathology in IFNAR1-KO
mice. Figure 2c shows that the lack of the IFNAR-1 re-
ceptor led to significantly reduced demyelination in CC,
when compared to C57BL/6 mice.
EAE and IFN-γ overcome dependency on type I IFN for
anti-MOG + C induced demyelination
To test whether demyelination was similarly affected by
type I IFN in mice with EAE, disease was induced by
immunization with MOG peptide 35–55 and CFA. The in-
cidence of EAE was almost two times higher in IFNAR1-
KO mice compared to C57BL/6 mice (64.3 versus 33.9%).
The time of onset of EAE was similar in C57BL/6 and
IFNAR1-KO (13.4 ± 0.6 versus 14.8 ± 0.7 days). At onset of
EAE, animals received anti-MOG + C or PBS by injection
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to CC (Fig. 3a). As expected, EAE was characterized by
prominent mononuclear cell infiltration throughout the
leptomeninges and white matter in the spinal cord (Add-
itional file 1). EAE severity at day 2 was 2.2 ± 0.2 and 3.2 ±
0.6 for C57BL/6 mice injected with PBS and anti-MOG +
C, respectively, and 2.3 ± 0.2 and 3.0 ± 0.4 for IFNAR1-KO
injected with PBS and anti-MOG + C, respectively. Im-
portantly there was no detectable pathology in the CC in
mice with EAE unless induced by focal injection of anti-
MOG and C (Fig. 3b). Callosal demyelination induced by
anti-MOG + C in C57BL/6 mice with pre-established EAE
was similar to that in mice without disease. Strikingly, the
anti-MOG + C-induced callosal demyelination was not dif-
ferent in IFNAR1-KO with pre-established EAE compared
to C57BL/6 mice.
The severity of EAE was not different between the
groups treated with PBS or anti-MOG + C either in
C57BL/6 or IFNAR1-KO, and the pattern of spinal cord
Fig. 1 Anti-MOG + C-mediated demyelination. a The left top panel shows a schematic drawing of the experimental setup showing how demyelination
was quantified. The degree of demyelination in percentage was measured as the loss of myelin (area of myelin loss) divided by area of corpus callosum
(CC area) in that hemisphere of the brain. The right top panel shows a dose response for demyelination in CC of C57BL/6 mice receiving purified mono-
clonal anti-MOG antibody from hybridoma clone Z2, along with C. Data are shown as mean ± SEM, the total number of animals in each group is shown
underneath columns, and this experiment was repeated only a single time with each dose. b Representative images of LFB and C9neo staining from
C57BL/6 mice injected with anti-MOG, control IgG2a+C and anti-MOG + C. Magnification: LFB (×4 and ×20) and C9neo (×20). c Quantitation of the
area of myelin loss in CC in C57BL/6 mice 2 days after injection of anti-MOG, control IgG2a+C, and anti-MOG + C as well as NOD-Scid/J immunodefi-
cient mice injected with anti-MOG + C and pathology. Statistical significance was assessed using two-tailed Mann–Whitney U test. Results are shown
as mean ± SEM, the total number of animals in each group is shown underneath columns. This experiment was repeated at least three times
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infiltration in IFNAR1-KO and C57BL/6 mice was un-
affected by intra-CC injection of anti-MOG + C or PBS
(Additional file 1). To ask whether the equivalence of de-
myelination between WT and IFNAR1-KO mice with
EAE could reflect inflammation-associated cytokines, we
administered IFN-γ to IFNAR1-KO mice. Figure 3c shows
that co-injection of IFN-γ into CC in IFNAR1-KO mice
along with anti-MOG + C led to demyelination at levels
equivalent to WT mice and so could compensate for the
lack of type I IFN signaling.
Discussion
We have shown that a MOG-specific antibody induced
C-dependent demyelination in the CC of mice.
Fig. 2 The influence of type I IFN signaling on antibody-mediated demyelination. a The left panel shows a bar graph with activation of astrocytes
and microglia in and around demyelinated areas in animals injected with anti-MOG + C or anti-MOG alone. The right panel shows representative
images of GFAP and Iba-1 staining from mice injected with anti-MOG + C. Results in the bar graph are shown as mean ± SEM of semi-
quantitative scores (arbitrary units), the total number of animals in each group is shown underneath columns. Original magnification in the repre-
sentative images is ×20. b Bar graphs showing IFN-β and CXCL10 gene expression in animals injected with anti-MOG + C, PBS, or anti-MOG alone.
Data are shown as mean ± SEM, the total number of animals in each group is shown underneath columns. The data represent pooled results
from at least three separate experiments. IFN-β gene expression was not detected (ND) in three samples from each group. c Anti-MOG + C was
injected into CC of either C57BL/6 or IFNAR1-deficient mice, and pathology was assessed 2 days later. Bar graph shows percentage demyelination.
Data were analyzed using two-tailed Mann–Whitney U test. Results are shown as mean + SEM, the total number of animals in each group is
shown underneath columns. The data represent pooled results from three separate experiments
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Fig. 3 EAE or administration of IFN-γ overcomes dependence on type I IFN for anti-MOG + C-induced demyelination. a C57BL/6 and IFNAR1-KO
mice were immunized with MOG35–55 as described in “Materials and methods.” At the onset of EAE, animals received either PBS or anti-MOG + C
by stereotactic injection into CC. The mice were then monitored for symptoms daily and sacrificed after 2 days. b Graphs showing the
quantification of demyelination. Data were analyzed using two-tailed Mann–Whitney U test. Results are shown as mean + SEM, the total number
of animals in each group is shown underneath columns. The data represent pooled results from three separate experiments. c Graph shows quan-
titation of the area of myelin loss. Comparison of first group (IFNAR1-KO alone) with middle group (IFNAR1-KO + rIFNgamma (50 ng)) shows that
induction of demyelination by the combination was equivalent to that in wild-type B6 mice (third group ). Statistical significance was assessed
using two-tailed Mann–Whitney U test. Results are shown as mean + SEM, the total number of animals in each group is shown underneath col-
umns. The data represent pooled results from at least three separate experiments
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Demyelination was similarly induced in NOD-Scid/J im-
munodeficient mice that lack T and B cells. We observed
that the type I IFN receptor is required for anti-MOG +
C-mediated demyelination. Remarkably, there was no ef-
fect of IFNAR1 deficiency on demyelination in CC in
mice with pre-established EAE. Thus, induction of EAE
overcame the dependence on type I IFN for anti-MOG
+ C-mediated demyelination in the CC. We could also
overcome the effect of IFNAR1 deficiency by co-
injection of IFN-γ. These findings show sufficiency of
myelin-specific antibody with C for white matter demye-
lination and a role for IFN signaling in promoting this.
These findings are novel, representing direct demonstra-
tion of pathogenicity of monoclonal anti-MOG antibody
in otherwise unmanipulated mice.
It has previously been shown that co-injection of anti-
MOG induced demyelination in an otherwise non-
demyelinating uniphasic EAE model in Lewis rats [21].
Demyelination was observed in the perivascular cuffs
and subpial bands of the white matter. Furthermore,
high titer anti-MOG-containing guinea pig serum has
been reported to induce demyelination when transferred
into subarachnoid space of normal rats [22]. Demyelin-
ation that was observed in the spinal cord was presumed
to reflect both the titer of antibody as well as serum
complement. Our study has taken this approach further
by using a monoclonal antibody of defined specificity in
CC and examining the role of type I IFN.
In a previous study, we demonstrated type I IFN in-
volvement in NMO-like pathology, showing reduced
NMO-like pathology in mice lacking the receptor for
type I IFN [24]. That finding was congruent with the
clinical disease NMO, which is refractory to IFN-β
treatment and may even be exacerbated by it [25, 30].
The involvement of type I IFN signaling in anti-MOG +
C-induced demyelination may reflect a general role for
IFN signaling. The mechanism whereby IFN signaling
promotes complement-dependent antibody-mediated
pathology, clearly of importance for inflammatory de-
myelinating diseases such as MS, remains to be
established.
By contrast with NMO, IFN-β is used to treat MS and
is effective against EAE. Over 50% of MS lesions have
been shown to involve antibody and C deposition on de-
myelinating axons, so at first glance, it seems contradict-
ory that IFN-β should have therapeutic benefit for MS
while promoting antibody-mediated demyelination.
However, therapeutic application of IFN-β in MS is via
peripheral injection, and relapse prevention may depend
on extra-CNS effects, as has been discussed [31]. Both
type I and II IFNs are expressed in the CNS of MS pa-
tients [31, 32], so IFN-dependent pathology should not
be impeded. Experimental models in which CNS-
endogenous type I IFN has been shown to be protective
are not noted for their dependence on antibody-
mediated pathology [33] and indeed may not require
antibodies or B cells at all [16]. Recently, it has been re-
ported that treatment with IFN-β in MOG-IgG-positive
patients was associated with increasing relapse rate [14].
It can be speculated that the lack of benefit of IFN-β in
antibody-mediated diseases in CNS such as NMO may
reflect the predominance of purely antibody-dependent
pathology. Better definition of the relative roles of type I
and II IFN in the CNS versus in the periphery will be
required for fuller understanding of this complex
interplay.
Stereotactic injection of a myelin-specific IgG antibody
with C to a white matter tract has allowed analysis of
focal demyelinating lesions that are independent of T or
B cells. This experimental system identifies sufficiency of
antibody and C for MS-like pathology and a role for IFN
signaling in promoting this. These findings will need to
be integrated to the much more complex inflammatory
environment in MS in which other pathological mecha-
nisms and many cell types also contribute.
Additional file
Additional file 1: H&E and LFB staining of spinal cord sections from
PBS- and anti-MOG + C-treated C57BL/6 and IFNAR1-KO mice with EAE.
Shown is dorsal horn of the lumbar spinal cord taken 2 days post-intra-
CC injection. There was no significant difference in EAE severity between
IFNAR1-KO and C57BL/6 mice. EAE severity was 2.2 ± 0.2 and 3.2 ± 0.6 for
C57BL/6 mice injected with PBS and anti-MOG + C, respectively, and
2.3 ± 0.2 and 3.0 ± 0.4 for IFNAR1-KO injected with PBS and anti-MOG + C,
respectively. H&E and LFB magnification: ×4 and ×20. (JPEG 375 kb)
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